
    
      This is a 4-week, randomized, double-blind, placebo-controlled study designed to assess the
      effects of the cholesterol absorption inhibitor HS-25 on LDL-C levels in adults who have
      untreated LDL-C levels ranging from 130-189 mg/dL and fasting triglyceride levels < 350
      mg/dL. Eligibility is restricted to 18-65 year old men or women who are using a highly
      effective birth control method or are not of childbearing potential. Patients with diabetes,
      a history of myocardial infarction or other clinical evidence of atherosclerotic vascular
      disease are not eligible for participation in the study.
    
  